$0.50
+0.01 (+2.28%)
Open$0.49
Previous Close$0.49
Day High$0.51
Day Low$0.48
52W High$2.11
52W Low$0.40
Volume—
Avg Volume188.1K
Market Cap10.54M
P/E Ratio—
EPS$-0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,496.8% upside
Current
$0.50
$0.50
Target
$8.04
$8.04
$5.03
$8.04 avg
$9.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.65M | 5.72M | 5.36M |
| Net Income | 307.3K | 283.7K | 353.7K |
| Profit Margin | 5.4% | 5.0% | 6.6% |
| EBITDA | 445.8K | 473.3K | 433.9K |
| Free Cash Flow | 346.8K | 407.6K | 312.1K |
| Rev Growth | +24.0% | +14.6% | +14.6% |
| Debt/Equity | 0.71 | 0.92 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |